Toll-Like Receptor 3 Antagonists
AssigneeJanssen Biotech, Inc.
InventorsMark Cunningham, Yiqing Feng, Katharine Heeringa, Jinquan Luo, Robert Rauchenberger, Mark Rutz, Lani San Mateo, Robert Sarisky, Raymond Sweet, Fang Teng, Alexey Teplyakov, Sheng-Jiun Wu
Life of this patent
Estimating the term…
Abstract
Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
Claims67
An isolated antibody or fragment thereof, wherein the antibody binds at least one toll-like receptor 3 (TLR3) amino acid residue selected from the group consisting of residues K467, R488 and R489 of SEQ ID NO:
- 2.
An isolated antibody or fragment thereof, wherein the antibody binds at least one TLR3 amino acid residue selected from the group consisting of residues D116 and K145 of SEQ ID NO:
- 2.
An isolated antibody or fragment reactive with TLR3, wherein the antibody has at least one of the following properties:
- a. reduces human TLR3 biological activity in an in vitro poly(I:C) NF-κB reporter gene assay >50% at <1 μg/ml;
- b. inhibits >60% of IL-6 or CXCL10/IP-10 production from BEAS-2B cells stimulated with <100 ng/ml poly(I:C) at <10 μg/ml;
- c. inhibits >50% of IL-6 or CXCL10/IP-10 production from BEAS-2B cells stimulated with <100 ng/ml poly(I:C) at <0.4 μg/ml;
- d. inhibits >50% of IL-6 production from NHBE cells stimulated with 62.5 ng/ml poly(I:C) at <5 μg/ml;
- e. inhibits >50% of IL-6 production from NHBE cells stimulated with 62.5 ng/ml poly(I:C) at <1 μg/ml;
- f. inhibits >20% of poly(I:C)-induced IFN-γ, IL-6 or IL-12 production by PBMC at <1 μg/ml;
- g. inhibits cynomologus TLR3 biological activity in an in vitro NF-kB reporter gene assay with IC50<10 μg/ml;
- or
- h. inhibits cynomologus TLR3 biological activity in an in vitro ISRE reporter gene assay with IC50<5 μg/ml.
An isolated antibody or fragment reactive with TLR3 that competes for TLR3 binding with a monoclonal antibody comprising:
- a. the heavy chain variable region of SEQ ID NO:
- 214;
- or
- b. the light chain variable region of SEQ ID NO:
- 211;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 214 and the light chain variable region of SEQ ID NO:
- 211;
- or
- d. the heavy chain complemetarity determining regions (CDR) 1, 2 and 3 (HCDR1, HCDR2 and HCDR3) amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72;
- or
- e. the light chain complemetarity determining regions (CDR) 1, 2 and 3 (LCDR1, LCDR2 and LCDR3) amino acid sequences as shown in SEQ ID NO:s 67, 68 and 78;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 78;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 214;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 211.
An isolated antibody or fragment reactive with TLR3 that competes for TLR3 binding with a monoclonal antibody comprising:
- a. the heavy chain variable region of SEQ ID NO:
- 216;
- or
- b. the light chain variable region of SEQ ID NO:
- 41;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 216 and the light chain variable region of SEQ ID NO:
- 41;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 86 and 84;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 87;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 86 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 87;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 216;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 41.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 192 and 60, wherein the HCDR2 of SEQ ID NO:
- 192 is further defined as shown in Formula (I):
- Xaa6-I-Xaa2-Xaa8-R-S-Xaa8-W-Y-N-D-Y-A-V-S-V-K-S, (I)
- wherein
- Xaa6 may be Arg or Lys;
- Xaa2 may be Tyr, His or Ser;
- Xaa8 may be Met, Arg or Tyr;
- and
- Xaa8 may be Lys or Arg;
- or
- b. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 191, wherein the LCDR3 of SEQ ID NO:
- 191 is further defined as shown in Formula (II):
- Xaa1-S-Y-D-Xaa2-Xaa2-Xaa4-Xaa5-T-V, (II)
- wherein
- Xaa1 may be Ala, Gln, Gly or Ser;
- Xaa2 may be Gly, Glu or Ser;
- Xaa3 may be Asp or Asn;
- Xaa4 may be Glu or Ser;
- and
- Xaa5 may be Phe, Ala or Leu;
- or
- c. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 192 and 60, wherein the HCDR2 of SEQ ID NO:
- 192 is further defined as shown in Formula (I):
- Xaa6-I-Xaa2-Xaa8-R-S-Xaa8-W-Y-N-D-Y-A-V-S-V-K-S, (I)
- wherein
- Xaa6 may be Arg or Lys;
- Xaa7 may be Tyr, His or Ser;
- Xaa8 may be Met, Arg or Tyr;
- and
- Xaa8 may be Lys or Arg;
- and
- the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 191, wherein the LCDR3 of SEQ ID NO:
- 191 is further defined as shown in Formula (II):
- Xaa1-S-Y-D-Xaa2-Xaa8-Xaa4-Xaa5-T-V, (II)
- wherein
- Xaa1 may be Ala, Gln, Gly or Ser;
- Xaa2 may be Gly, Glu or Ser;
- Xaa8 may be Asp or Asn;
- Xaa4 may be Glu or Ser;
- and
- Xaa5 may be Phe, Ala or Leu;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 194 and 72, wherein the HCDR2 of SEQ ID NO:
- 194 is further defined as shown in Formula (III):
- I-I-Q-Xaa15-R-S-K-W—Y-N-Xaa16-Y-A-Xaa17-S-V-K-S, (III)
- wherein
- Xaam may be Lys, Thr or Ile;
- Xaam may be Asn or Asp;
- and
- Xaa17 may be Val or Leu;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 193, wherein the LCDR3 of SEQ ID NO:
- 193 is further defined as shown in Formula (IV):
- Xaa10-S-Y-D-Xaa11-P-Xaa12-Xaa13-Xaa14-V, (IV)
- Wherein
- Xaa10 may be Gln or Ser;
- Xaa11 may be Thr, Glu or Asp;
- Xaa12 may be Val or Asn;
- Xaa13 may be Tyr or Phe;
- and
- Xaa14 may be Ser, Asn or Gln;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 194 and 72, wherein the HCDR2 of SEQ ID NO:
- 194 is further defined as shown in Formula (III):
- I-I-Q-Xaa15-R-S-K-W—Y-N-Xaa16-Y-A-Xaa17-S-V-K-S, (III)
- wherein
- Xaa15 may be Lys, Thr or Ile;
- Xaa16 may be Asn or Asp;
- and
- Xaa17 may be Val or Leu;
- and
- the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 193, wherein the LCDR3 of SEQ ID NO:
- 193 is further defined as shown in Formula (IV):
- Xaa10-S-Y-D-Xaa11-P-Xaa12-Xaa13-Xaa14-V, (IV)
- Wherein
- Xaa10 may be Gln or Ser;
- Xaa11 may be Thr, Glu or Asp;
- Xaa12 may be Val or Asn;
- Xaa13 may be Tyr or Phe;
- and
- Xaa14 may be Ser, Asn or Gln.
- g. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 196 and 84, wherein the HCDR2 of SEQ ID NO:
- 196 is further defined as shown in Formula (V):
- Xaa24-I-D-P-S-D-S-Y-T-N-Y-Xaa25-P-S-F-Q-G, (V)
- wherein
- Xaa24 may be Phe or Arg;
- and
- Xaa25 may be Ala or Ser;
- or
- h. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 195, wherein the LCDR3 of SEQ ID NO:
- 195 is further defined as shown in Formula (VI):
- Q-Q-Xaa18-Xaa19-Xaa20-Xaa21-Xaa22-Xaa23-T, (VI)
- wherein
- Xaa18 may be Tyr, Gly or Ala;
- Xaa19 may be Gly, Glu or Asn;
- Xaa20 may be Ser or Thr;
- Xaa21 may be Val, Ile or Leu;
- Xaa22 may be Ser or Leu;
- and
- Xaa23 may be Ile, Ser, Pro or Tyr;
- or
- i. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 196 and 84, wherein the HCDR2 of SEQ ID NO:
- 196 is further defined as shown in Formula (V):
- Xaa24-I-D-P-S-D-S-Y-T-N-Y-Xaa25-P-S-F-Q-G, (V)
- wherein
- Xaa24 may be Phe or Arg;
- and
- Xaa25 may be Ala or Ser;
- and
- j. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 195, wherein the LCDR3 of SEQ ID NO:
- 195 is further defined as shown in Formula (VI):
- Q-Q-Xaa18Xaa19-Xaa20-Xaa21-Xaa22-Xaa23-T, (VI)
- wherein
- Xaa18 may be Tyr, Gly or Ala;
- Xaa19 may be Gly, Glu or Asn;
- Xaa20 may be Ser or Thr;
- Xaa21 may be Val, Ile or Leu;
- Xaa22 may be Ser or Leu;
- and
- Xaa23 may be Ile, Ser, Pro or Tyr.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 6;
- or
- b. the light chain variable region of SEQ ID NO:
- 5;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 6 and the light chain variable region of SEQ ID NO:
- 5;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 52, 88 and 54;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 49, 50 and 51;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 52, 88 and 54;
- and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 49, 50 and 51;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 7;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 6.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 8;
- or
- b. the light chain variable region of SEQ ID NO:
- 7;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 8 and the light chain variable region of SEQ ID NO:
- 7;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 58, 64 and 60;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 58, 64 and 60 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 8;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 7.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 10;
- or
- b. the light chain variable region of SEQ ID NO:
- 9;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 10 and the light chain variable region of SEQ ID NO:
- 9;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 10;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 9.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 12;
- or
- b. the light chain variable region of SEQ ID NO:
- 11;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 12 and the light chain variable region of SEQ ID NO:
- 11;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 83 and 84;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 89;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 83 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 89;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 12;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 11.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 14;
- or
- b. the light chain variable region of SEQ ID NO:
- 13;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 14 and the light chain variable region of SEQ ID NO:
- 13;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 46, 47 and 48;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 43, 44 and 45;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 46, 47 and 48 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 43, 44 and 45;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 14;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 13.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 16;
- or
- b. the light chain variable region of SEQ ID NO:
- 15;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 16 and the light chain variable region of SEQ ID NO:
- 15;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 52, 53 and 54;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 49, 50 and 51;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 52, 53 and 54 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 49, 50 and 51;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 16;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 15.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 18;
- or
- b. the light chain variable region of SEQ ID NO:
- 17;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 18 and the light chain variable region of SEQ ID NO:
- 17;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 58, 59 and 60;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 58, 59 and 60 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 18;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 17.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 20;
- or
- b. the light chain variable region of SEQ ID NO:
- 19;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 20 and the light chain variable region of SEQ ID NO:
- 19;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 62 and 60;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 62 and 60 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 20;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 19.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 22;
- or
- b. the light chain variable region of SEQ ID NO:
- 21;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 22 and the light chain variable region of SEQ ID NO:
- 21;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 64 and 60;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 63;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 64 and 60 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 63;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 22;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 21.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 24;
- or
- b. the light chain variable region of SEQ ID NO:
- 23;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 24 and the light chain variable region of SEQ ID NO:
- 23;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s s 61, 64 and 60;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 65;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 64 and 60 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 65;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 24;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 23.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 26;
- or
- b. the light chain variable region of SEQ ID NO:
- 25;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 26 and the light chain variable region of SEQ ID NO:
- 25;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 64 and 60;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 66;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 64 and 60 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 66;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 26;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 25.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 28;
- or
- b. the light chain variable region of SEQ ID NO:
- 27;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 28 and the light chain variable region of SEQ ID NO:
- 27;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 71 and 72;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 71 and 72 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 28;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 27.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 30;
- or
- b. the light chain variable region of SEQ ID NO:
- 29;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 30 and the light chain variable region of SEQ ID NO:
- 29;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 73 and 72;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 73 and 72 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 30;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 29.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 32;
- or
- b. the light chain variable region of SEQ ID NO:
- 31;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 32 and the light chain variable region of SEQ ID NO:
- 31;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 75 and 72;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 74;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 75 and 72 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 74;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 32;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 31.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 34;
- or
- b. the light chain variable region of SEQ ID NO:
- 33;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 34 and the light chain variable region of SEQ ID NO:
- 33;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 76;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 76;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 34;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 33.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 36;
- or
- b. the light chain variable region of SEQ ID NO:
- 35;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 36 and the light chain variable region of SEQ ID NO:
- 35;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 78;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 78;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 36;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 35.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 38;
- or
- b. the light chain variable region of SEQ ID NO:
- 37;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 38 and the light chain variable region of SEQ ID NO:
- 37;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 83 and 84;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 81;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 83 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 81;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 38;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 37.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 40;
- or
- b. the light chain variable region of SEQ ID NO:
- 39;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 40 and the light chain variable region of SEQ ID NO:
- 39;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 86 and 84;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 85;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 86 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 85;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 40;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 39;
- i. the heavy chain of SEQ ID NO:
- 102;
- or
- j. the light chain of SEQ ID NO:
- 155;
- or
- k. the heavy chain of SEQ ID NO:
- 102 and the light chain of SEQ ID NO:
- 155.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 42;
- or
- b. the light chain variable region of SEQ ID NO:
- 41;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 42 and the light chain variable region of SEQ ID NO:
- 41;
- or
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 86 and 84;
- or
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 87;
- or
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 86 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 87;
- or
- g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 42;
- or
- h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO:
- 41;
- i. the heavy chain of SEQ ID NO:
- 102;
- or
- j. the light chain of SEQ ID NO:
- 156;
- or
- k. the heavy chain of SEQ ID NO:
- 102 and the light chain of SEQ ID NO:
- 156.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 216;
- or
- b. the light chain variable region of SEQ ID NO:
- 41;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 216 and the light chain variable region of SEQ ID NO:
- 41;
- or
- d. the heavy chain of SEQ ID NO:
- 220;
- or
- e. the light chain of SEQ ID NO:
- 156;
- or
- f. the heavy chain of SEQ ID NO:
- 220 and the light chain of SEQ ID NO:
- 156.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 124;
- or
- b. the heavy chain variable region of SEQ ID NO:
- 125;
- or
- c. the heavy chain variable region of SEQ ID NO:
- 126;
- or
- d. the heavy chain variable region of SEQ ID NO:
- 127;
- or
- e. the heavy chain variable region of SEQ ID NO:
- 128;
- or
- f. the heavy chain variable region of SEQ ID NO:
- 129;
- or
- g. the heavy chain variable region of SEQ ID NO:
- 124 and the light chain variable region of SEQ ID NO:
- 41;
- or
- h. the heavy chain variable region of SEQ ID NO:
- 125 and the light chain variable region of SEQ ID NO:
- 41;
- or
- i. the heavy chain variable region of SEQ ID NO:
- 126 and the light chain variable region of SEQ ID NO:
- 41;
- or
- j. the heavy chain variable region of SEQ ID NO:
- 127 and the light chain variable region of SEQ ID NO:
- 41;
- or
- k. the heavy chain variable region of SEQ ID NO:
- 128 and the light chain variable region of SEQ ID NO:
- 41;
- or
- the heavy chain variable region of SEQ ID NO:
- 129 and the light chain variable region of SEQ ID NO:
- 41;
- or
- m. the light chain variable region of SEQ ID NO:
- 122;
- or
- n. the light chain variable region of SEQ ID NO:
- 123;
- or
- o. the heavy chain variable region of SEQ ID NO:
- 42 and the light chain variable region of SEQ ID NO:
- 122;
- or
- p. the heavy chain variable region of SEQ ID NO:
- 42 and the light chain variable region of SEQ ID NO:
- 123;
- or
- q. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 112 and 84;
- or
- r. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 114 and 84;
- or
- s. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 115, 112 and 84;
- or
- t. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 112 and 84;
- or
- u. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 117 and 84;
- or
- v. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 118 and 84;
- or
- w. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 112 and 119;
- or
- x. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 118 and 119;
- or
- y. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 112 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113;
- or
- z. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 114 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113;
- or
- aa. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 115, 112 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113;
- or
- bb. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 112 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113;
- or
- cc. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 117 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113;
- or
- dd. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 118 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113;
- or
- ee. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 112 and 119 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113;
- or
- ff. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 120, 110 and 113;
- or
- gg. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 121, 110 and 113;
- or
- hh. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 112 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 120, 110 and 113;
- or
- ii. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 112 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 121, 110 and 113;
- or
- jj. the heavy chain of SEQ ID NO:
- 130;
- or
- kk. the heavy chain of SEQ ID NO:
- 131;
- or
- ll. the heavy chain of SEQ ID NO:
- 132;
- or
- mm. the heavy chain of SEQ ID NO:
- 133;
- or
- nn. the heavy chain of SEQ ID NO:
- 134;
- or
- oo. the heavy chain of SEQ ID NO:
- 135;
- or
- pp. the heavy chain of SEQ ID NO:
- 160;
- or
- qq. the heavy chain of SEQ ID NO:
- 130 and the light chain of SEQ ID NO:
- 156;
- or
- rr. the heavy chain of SEQ ID NO:
- 131 and the light chain of SEQ ID NO:
- 156;
- or
- ss. the heavy chain of SEQ ID NO:
- 132 and the light chain of SEQ ID NO:
- 156;
- or
- tt. the heavy chain of SEQ ID NO:
- 133 and the light chain of SEQ ID NO:
- 156;
- or
- uu. the heavy chain of SEQ ID NO:
- 134 and the light chain of SEQ ID NO:
- 156;
- or
- vv. the heavy chain of SEQ ID NO:
- 135 and the light chain of SEQ ID NO:
- 156;
- or
- ww. the heavy chain of SEQ ID NO:
- 160 and the light chain of SEQ ID NO:
- 156;
- or
- xx. the light chain of SEQ ID NO:
- 157;
- or
- yy. the light chain of SEQ ID NO:
- 158;
- or
- zz. the heavy chain of SEQ ID NO:
- 102 and the light chain of SEQ ID NO:
- 157;
- or
- aaa. the heavy chain of SEQ ID NO:
- 102 and the light chain of SEQ ID NO:
- 158.
An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
- a. the heavy chain variable region of SEQ ID NO:
- 164;
- or
- b. the light chain variable region of SEQ ID NO:
- 163;
- pr
- c. the heavy chain variable region of SEQ ID NO:
- 164 and
- d. the light chain variable region of SEQ ID NO:
- 163;
- or
- e. the heavy chain of SEQ ID NO:
- 166;
- or
- f. the light chain of SEQ ID NO:
- 165;
- or
- g. the heavy chain of SEQ ID NO:
- 166 and the light chain of SEQ ID NO:
- 165;
- or
- h. the heavy chain of SEQ ID NO:
- 168;
- or
- i. the light chain of SEQ ID NO:
- 167;
- or
- j. the heavy chain of SEQ ID NO:
- 168 and the light chain of SEQ ID NO:
- 167.
An isolated polynucleotide encoding an antibody heavy chain comprising the CDR amino acid sequences selected from the group consisting of:
- a. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 192 and 60, wherein the HCDR2 of SEQ ID NO:
- 192 is further defined as shown in Formula (I):
- Xaa6-I-Xaa7-Xaa8-R-S-Xaa9-W-Y-N-D-Y-A-V-S-V-K-S
- wherein
- Xaa6 may be Arg or Lys;
- Xaa7 may be Tyr, His or Ser;
- Xaa8 may be Met, Arg or Tyr;
- and
- Xaa8 may be Lys or Arg;
- b. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 194 and 72, wherein the HCDR2 of SEQ ID NO:
- 194 is further defined as shown in Formula (III):
- I-I-Q-Xaa15-R-S-K-W—Y-N-Xaa16-Y-A-Xaa17-S-V-K-S
- wherein
- Xaa15 may be Lys, Thr or Ile;
- Xaa16 may be Asn or Asp;
- and
- Xaa17 may be Val or Leu.
- c. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 196 and 84, wherein the HCDR2 of SEQ ID NO:
- 196 is further defined as shown in Formula (V):
- Xaa24-I-D-P-S-D-S-Y-T-N-Y-Xaa25-P-S-F-Q-G
- wherein
- Xaa24 may be Phe or Arg;
- and
- Xaa25 may be Ala or Ser;
- d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 52, 88 and 54;
- e. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 58, 64 and 60;
- f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s SEQ ID NOs:
- 70, 77 and 72;
- g. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 83 and 84;
- h. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 46, 47 and 48;
- i. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 52, 53 and 54;
- j. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 58, 59 and 60;
- k. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 62 and 60;
- l. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 64 and 60;
- m. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 71 and 72;
- n. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 73 and 72;
- o. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 75 and 72;
- p. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72;
- q. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 83 and 84;
- r. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 86 and 84;
- s. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 114 and 84;
- t. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 115, 112 and 84;
- u. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 112 and 84;
- v. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 117 and 84;
- w. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 118 and 84;
- x. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 112 and 119;
- and
- y. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 118 and 119.
An isolated polynucleotide encoding an antibody light chain comprising the CDR amino acid sequences selected from the group consisting of:
- a. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 191, wherein the LCDR3 of SEQ ID NO:
- 191 is further defined as shown in Formula (II):
- Xaa1-S-Y-D-Xaa2-Xaa2-Xaa4-Xaa5-T-V, (II)
- wherein
- Xaa1 may be Ala, Gln, Gly or Ser;
- Xaa2 may be Gly, Glu or Ser;
- Xaa3 may be Asp or Asn;
- Xaa4 may be Glu or Ser;
- and
- Xaa5 may be Phe, Ala or Leu;
- or
- b. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 193, wherein the LCDR3 of SEQ ID NO:
- 193 is further defined as shown in Formula (IV):
- Xaa10-S-Y-D-Xaa11-P-Xaa12-Xaa12-Xaa14-V, (IV)
- Wherein
- Xaa10 may be Gln or Ser;
- Xaa11 may be Thr, Glu or Asp;
- Xaa12 may be Val or Asn;
- Xaa13 may be Tyr or Phe;
- and
- Xaa14 may be Ser, Asn or Gln;
- or
- c. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 195, wherein the LCDR3 of SEQ ID NO:
- 193 is further defined as shown in Formula (VI):
- Q-Q-Xaa18-Xaa19-Xaa20-Xaa20-Xaa22-Xaa22T, (VI)
- wherein
- Xaa18 may be Tyr, Gly or Ala;
- Xaa19 may be Gly, Glu or Asn;
- Xaa20 may be Ser or Thr;
- Xaa21 may be Val, Ile or Leu;
- Xaa22 may be Ser or Leu;
- and
- Xaa22 may be Ile, Ser, Pro or Tyr;
- or
- d. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 49, 50 and 51;
- e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57;
- f. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69;
- g. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 89;
- h. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 43, 44 and 45;
- i. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 49, 50 and 51;
- j. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57;
- k. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 63;
- l. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 65;
- m. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 66;
- n. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69;
- o. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 74;
- p. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 76;
- q. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 78;
- r. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 81;
- s. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 85;
- t. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 87;
- u. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113;
- v. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 120, 110 and 113;
- and
- w. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 121, 110 and 113;
An isolated polynucleotide encoding an antibody heavy chain comprising the amino acid sequence shown in SEQ ID NO:
- 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 124, 125, 126, 127, 128, 129, 159, 198, 200, 202, 164, 212, 213, 214, 215 or 216.
An isolated polynucleotide encoding an antibody light chain comprising the amino acid sequence shown in SEQ ID NO:
- 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 122, 123, 197, 199, 201, 163, 209, 210 or 211.
An isolated polynucleotide encoding an antibody heavy chain comprising the amino acid sequence shown in SEQ ID NO:
- 102, 130, 131, 132, 133, 134, 135, 160, 204, 206, 208, 220, 166 or 168.
An isolated polynucleotide encoding an antibody light chain comprising the amino acid sequence shown in SEQ ID NO:
- 155, 156, 157, 158, 203, 205, 207, 165 or 167.
An isolated antibody heavy chain comprising the amino acid sequence shown in SEQ ID NO:
- 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 124, 125, 126, 127, 128, 129, 159, 198, 200, 202, 164, 212, 213, 214, 215 or 216.
An isolated antibody light chain comprising the amino acid sequence shown in SEQ ID NO:
- 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 122, 123, 197, 199, 201, 163, 209, 210 or 211.
An isolated antibody heavy chain comprising the amino acid sequence shown in SEQ ID NO:
- 102, 130, 131, 132, 133, 134, 135, 160, 204, 206, 208, 220, 166 or 168.
An isolated antibody light chain comprising the amino acid sequence shown in SEQ ID NO:
- 155, 156, 157, 158, 203, 205, 207, 165 or 167.
Dependencies are inferred from the claim text.